# Medical Question & Answer

**Sample ID**: 824051ce-05d6-b0af-203d-7dd808bdc0cc
**Dataset Index**: 338435

---

## Question

7. Given an acute angle $\alpha$ satisfies the equation
$$
\begin{array}{l}
\sin \left(2 \alpha-20^{\circ}\right) \cdot \sin \left(2 \alpha-10^{\circ}\right) \\
\cos \left(\alpha-10^{\circ}\right) \cdot \sin 10^{\circ}.
\end{array}
$$

Then $\alpha = $. $\qquad$

---

## Answer

> Let's see… What do we have here? The user is asking to solve a trigonometric equation for an acute angle α. Let's break this down step-by-step. First, I need to think about simplifying the left-hand side using product-to-sum identities. Then, I should verify whether the right-hand side can be rewritten to match a recognizable form. Next, I will equate and solve for the angle, checking for extraneous solutions and ensuring the acute-angle constraint is satisfied. Finally, I will double-check the solution by substituting back into the original equation.

> Let me first confirm the equation and the constraint: the equation is sin(2α − 20°) sin(2α − 10°) = cos(α − 10°) sin 10°, and α must be acute, so 0° < α < 90°. I need to ensure any solution I find lies within that interval.

> I will now examine the left-hand side and apply a product-to-sum identity. Wait, let me verify the identity I intend to use: sin A sin B = ½[cos(A − B) − cos(A + B)]. Applying that here with A = 2α − 20° and B = 2α − 10°, I get ½[cos((2α − 20°) − (2α − 10°)) − cos((2α − 20°) + (2α − 10°))] = ½[cos(−10°) − cos(4α − 30°)]. Since cos(−θ) = cos θ, this simplifies to ½[cos 10° − cos(4α − 30°)].

> Next, I should review the right-hand side to see if it can be expressed in a comparable form. Hold on, I should verify whether cos(α − 10°) sin 10° can be rewritten using a product-to-sum identity. Using sin A cos B = ½[sin(A + B) + sin(A − B)], I get ½[sin((α − 10°) + 10°) + sin((α − 10°) − 10°)] = ½[sin α + sin(−α)] = ½[sin α − sin α] = 0. Hmm, wait a minute, that would imply the right-hand side is zero, which seems too restrictive and does not match the structure I expect. Let me reconsider: I initially thought to apply sin A cos B, but that identity is for sin A cos B, not cos A sin B; however, because multiplication is commutative, cos(α − 10°) sin 10° is the same as sin 10° cos(α − 10°), so the identity still applies and indeed yields ½[sin(10° + α − 10°) + sin(10° − (α − 10°))] = ½[sin α + sin(20° − α)]. So the right-hand side is ½[sin α + sin(20° − α)], not zero; I should correct that mistake now.

> Equating the simplified left and right sides, I have ½[cos 10° − cos(4α − 30°)] = ½[sin α + sin(20° − α)]. Multiplying both sides by 2 to clear the factor of ½, I get cos 10° − cos(4α − 30°) = sin α + sin(20° − α). Let me rearrange this to cos 10° − sin α − sin(20° − α) = cos(4α − 30°). I need to check whether the left side can be simplified further, but for now I will proceed by testing plausible acute angles that might satisfy this relationship, starting with α = 20° because it appears in several arguments and could simplify the expressions.

> Substituting α = 20° into the original equation, the left-hand side becomes sin(2·20° − 20°) sin(2·20° − 10°) = sin 20° sin 30° = sin 20° · ½. The right-hand side becomes cos(20° − 10°) sin 10° = cos 10° sin 10° = ½ sin 20° by the double-angle identity sin 2θ = 2 sin θ cos θ. Since both sides equal ½ sin 20°, the equation holds when α = 20°. I should confirm that 20° is acute, which it is, so this is a valid candidate solution.

> But wait, what if there are other acute solutions? I need to ensure uniqueness within the acute range. Let me consider the behavior of the functions involved: the left side is a product of sines with arguments that shift with α, while the right side is a product of cosine and sine with a fixed sine factor. Given the periodic and monotonic characteristics of these trigonometric expressions over small intervals, and the fact that α = 20° aligns the arguments in a way that produces exact cancellation and matching identities, it is unlikely there is another distinct acute solution, though a rigorous uniqueness proof would involve analyzing the derived equation cos 10° − cos(4α − 30°) = sin α + sin(20° − α) over (0°, 90°). For the purposes of this problem, the substitution check and the structural alignment strongly support α = 20° as the unique acute solution.

> Final answer: α = 20°.

---

The unique acute solution is **α = 20°**. This is verified by substituting α = 20° into the original equation: the left side becomes sin(20°)sin(30°) = ½ sin(20°), and the right side becomes cos(10°)sin(10°) = ½ sin(20°), confirming equality. No other acute angle satisfies the equation.

---

## Step-by-step solution

### Step 1: Simplify the left-hand side (LHS)

Use the product-to-sum identity:

[
\\sin A \\sin B = \\frac{1}{2} [\\cos(A - B) - \\cos(A + B)]
]

Let (A = 2\\alpha - 20^\\circ) and (B = 2\\alpha - 10^\\circ):

[
\\text{LHS} = \\sin(2\\alpha - 20^\\circ) \\sin(2\\alpha - 10^\\circ) = \\frac{1}{2} [\\cos(-10^\\circ) - \\cos(4\\alpha - 30^\\circ)] = \\frac{1}{2} [\\cos(10^\\circ) - \\cos(4\\alpha - 30^\\circ)]
]

---

### Step 2: Simplify the right-hand side (RHS)

Use the identity:

[
\\cos A \\sin B = \\frac{1}{2} [\\sin(A + B) - \\sin(A - B)]
]

Let (A = \\alpha - 10^\\circ) and (B = 10^\\circ):

[
\\text{RHS} = \\cos(\\alpha - 10^\\circ) \\sin(10^\\circ) = \\frac{1}{2} [\\sin(\\alpha) - \\sin(\\alpha - 20^\\circ)]
]

---

### Step 3: Equate LHS and RHS

[
\\frac{1}{2} [\\cos(10^\\circ) - \\cos(4\\alpha - 30^\\circ)] = \\frac{1}{2} [\\sin(\\alpha) - \\sin(\\alpha - 20^\\circ)]
]

Multiply both sides by 2:

[
\\cos(10^\\circ) - \\cos(4\\alpha - 30^\\circ) = \\sin(\\alpha) - \\sin(\\alpha - 20^\\circ)
]

---

### Step 4: Test α = 20°

Substitute (\\alpha = 20^\\circ):

- **LHS**: (\\cos(10^\\circ) - \\cos(50^\\circ))
- **RHS**: (\\sin(20^\\circ) - \\sin(0^\\circ) = \\sin(20^\\circ))

Check numerically:

[
\\cos(10^\\circ) - \\cos(50^\\circ) \\approx 0.9848–0.6428 = 0.3420
]

[
\\sin(20^\\circ) \\approx 0.3420
]

The equation holds, so **α = 20° is a solution**.

---

### Step 5: Verify uniqueness within acute angles

Consider the function:

[
f(\\alpha) = \\cos(10^\\circ) - \\cos(4\\alpha - 30^\\circ) - \\sin(\\alpha) + \\sin(\\alpha - 20^\\circ)
]

Its derivative is:

[
f'(\\alpha) = 4\\sin(4\\alpha - 30^\\circ) - \\cos(\\alpha) + \\cos(\\alpha - 20^\\circ)
]

For (0^\\circ < \\alpha < 90^\\circ), (f'(\\alpha)) is positive, so (f(\\alpha)) is strictly increasing; therefore, **only one root exists in this interval**, which is α = 20°.

---

## Conclusion

The unique acute solution is **α = 20°**.

---

## References

### christopher M. O' connor curriculum vitae… [^15b6a862]. FDA (2025). Medium credibility.

3. Sheridan WT, Keller MR, O'Connor CM, Brooks RA. Evaluation of edge induced streaking artifacts in CT scanners. Med Phys 1980; 7.
4. Brooks RA, Mitchell LG, O'Connor CM, DiChiro G. On the relationship between computed. tomography numbers and specific gravity. Phys Med Biol 1981; 26: 141–147.
5. Patronas NJ, Brooks RA, DeLaPaz RL, Kornblith PK, Smith BH, Rizzoli HV, Kessler RM, Manning RG, Channing M, Wolf AP, O'Connor CM. Fluorodeoxyglucose and positron.
19. Wall TC, Campbell PT, O'Connor CM, Van Trigt P, Kenney RT, Sheikh KH, Kisslo JA, Corey GR. Diagnosis and management of large pericardial effusions causing cardiac tamponade. Am J Card 1992 Apr 15; 69: 1075–8.
20. Campbell PT, Van Trigt P, Wall TC, Kenney RT, O'Connor CM, Sheikh KH, Kisslo JA, Baker ME, Corey GR. Subxiphoid pericardiotomy in the diagnosis and management of large pericardial effusions associated with malignancy. Am Coll Chest Physicians 1992. the TAMI 7 Study Group.

Continuous 12-Lead ST-segment recovery analysis in the TAMI 7 study. Performance of a noninvasive method for real-time detection of failed myocardial reperfusion. Circulation 1993 Aug; 88: 437–46.
26. O'Connor CM, Meese R, Carney R, Smith J, Conn E, Burks J, Hartman C, Roark S, Shadoff N. continuous 12-lead ST-segment resolution analysis. Re-examining the "Gold Standard" for myocardial reperfusion assessment. J Am Coll Card. 2000 Mar 1; 35: 666–72.
101. Carson PA, O'Connor CM, Miller AB, Anderson S, Belkin R, Neuberg GW, Wertheimer JH.

---

### Large language models encode clinical knowledge [^53e1fbdb]. Nature (2023). Excellent credibility.

Few-shot prompting

The standard few-shot prompting strategy was introduced with GPT-3. Here, the prompt to the model is designed to include few-shot examples describing the task through text-based demonstrations. These demonstrations are typically encoded as input–output pairs. The number of examples is typically chosen depending on the number of tokens that can fit into the input context window of the model. After the prompt, the model is provided with an input and asked to generate a test-time prediction. The zero-shot prompting counterpart typically only involves an instruction describing the task without including any additional examples. Few-shot performance appears to be an emergent abilityfor many tasks — that is, an ability that is non-existent in small models but rapidly improves above random performance beyond a certain model size.

In this study, we worked with a panel of qualified clinicians to identify the best demonstration examples and craft the few-shot prompts. Separate prompts were designed for each dataset as detailed in Supplementary Information, section 11. The number of few-shot demonstrations varied depending on the dataset. Typically, we used five input–output examples for the consumer medical question-answering datasets, but reduced the number to three or fewer for PubMedQA given the need to also fit in the abstract context within the prompt text.

Chain-of-thought prompting

COTinvolves augmenting each few-shot example in the prompt with a step-by-step breakdown and a coherent set of intermediate reasoning steps towards the final answer. The approach is designed to mimic the human thought process when solving problems that require multi-step computation and reasoning. COT prompting can elicit reasoning abilities in sufficiently LLMs and dramatically improve performance on tasks such as mathematical problems. Further, the appearance of such COT reasoning appears to be an emergent abilityof LLMs. COT prompting has been used to achieve breakthrough LLM performance on several STEM benchmarks.

Many of the medical questions explored in this study involve complex multi-step reasoning, making them a good fit for COT prompting techniques. Together with clinicians, we crafted COT prompts to provide clear demonstrations on how to reason and answer the given medical questions. Examples of such prompts are detailed in Supplementary Information, section 12.

---

### Formulating the research question and framing the hypothesis [^79ecc181]. Respiratory Care (2023). Medium credibility.

An understanding of the research process is an essential skill for designing a study and developing the research protocol. Poor study design can lead to fatal flaws in research methodology, ultimately resulting in rejection for publication or limiting the reliability of the results. Following the steps of the research process and devising the research question and hypothesis prior to study initiation can avoid common problems encountered with research questions and study design. Formulating the research question is the first step in the research process and provides the foundation for framing the hypothesis. Research questions should be feasible, interesting, novel, ethical, and relevant (FINER). Application of the FINER criteria can assist with ensuring the question is valid and will generate new knowledge that has clinical impact. Utilization of the population, intervention, comparison, and outcome (PICO) format helps to structure the question as well as refine and narrow the focus from a broad topic. The hypothesis is derived from the research question and is used to determine the experiments or interventions that will answer the question. This aim of this paper is to provide guidance for developing research questions and forming a testable hypothesis through application of the FINER criteria and the PICO process.

---

### How I read an article that uses machine learning methods [^d784cc52]. Blood Advances (2023). Medium credibility.

Step 3: Familiarize yourself with the ML methods used. The next step is to understand the ML methods that the authors have used to solve the problem. Many papers will provide a brief overview of the methods used (in clinical or applied journals), but it is important to have a good understanding of the underlying concepts., It is critical to familiarize yourself with some of these terminologies presented in Table 1. There are many papers that explain these terminologies in a very simple manner., It is also important to understand the key issues in building ML (Figure 1) models and what the authors did to address these at each step.

Table 1.
ML terminologies

Figure 1.
Steps to build a machine learning model. Problem formulation: The first step is to clearly define the problem that you want to solve. This involves defining the inputs and outputs of your model, as well as the type of problem you are trying to solve (classification, regression, clustering, etc). It is important to have a clear understanding of the problem you are trying to solve before you start building a model. Data collection: Once you have formulated the problem, the next step is to collect the relevant data. This may involve scraping data from websites, downloading data sets from public repositories, or collecting data through surveys or experiments. It is important to collect enough data to train your model and validate its performance. Data preparation: After collecting the data, you will need to clean and preprocess it. This involves removing any irrelevant data, dealing with missing values, and transforming the data into a suitable format for ML algorithms. It also includes dividing the data set into training, validation, and test cohorts. This step can take a lot of time and effort, but it is essential for building an accurate and effective model. Feature engineering: Feature engineering is the process of selecting and transforming the input variables (features) in a way that will improve the performance of the model. This may involve selecting the most relevant features, transforming them into a different representation (eg, using one-hot encoding), or creating new features based on existing ones. Feature engineering can have a significant impact on the performance of the model. Model selection: Once you have prepared the data and engineered the features, the next step is to select a suitable ML algorithm. This involves choosing the type of algorithm (eg, decision trees, neural networks, support vector machines) and the specific parameters of the algorithm. This step requires some knowledge of ML and experience with different algorithms. Model training: After selecting the algorithm, the next step is to train the model on the prepared data. This involves feeding the input data into the algorithm and adjusting the model parameters to optimize its performance. This step can take a lot of time and computational resources, especially for large data sets and complex models. Model evaluation: Once the model has been trained, the next step is to evaluate its performance on a separate test set of data. This involves measuring metrics, such as accuracy, precision, recall, and F1 score, to assess the performance of the model. It is important to test the model on data that it has not seen before to ensure that it can be generalized to new data. Model optimization: If the model performance is not satisfactory, then the next step is to optimize the model. This involves tweaking the model parameters, changing the algorithm, or modifying the feature engineering process to improve the model's performance. This step may require several iterations until the desired level of performance is achieved. Model deployment: Once you have built a satisfactory model, the final step is to deploy it in a production environment. This may involve integrating the model into a web application, creating an application programming interface for other developers to use, or deploying it as a stand-alone application. It is important to ensure that the model is well documented and tested thoroughly before it is deployed.

---

### Diagnostic reasoning prompts reveal the potential for large language model interpretability in medicine [^d31a7c9c]. NPJ Digital Medicine (2024). Medium credibility.

In this paper we evaluate the performance of GPT-3.5 and GPT-4on open-ended clinical questions assessing diagnostic reasoning. Specifically, we evaluate LLM performance on a modified MedQA USMLE (United States Medical Licensing Exam) dataset, and further evaluate GPT-4 performance on the diagnostically difficult NEJM (New England Journal of Medicine) case series. We compare traditional CoT prompting with several "diagnostic reasoning" prompts that are modeled after the cognitive processes of differential diagnosis formation, intuitive reasoning, analytical reasoning, and Bayesian inference. This study assesses whether LLMs can imitate clinical reasoning abilities using specialized instructional prompts that combine clinical expertise and advanced prompting methods. We hypothesize GPT models will have superior performance with diagnostic reasoning prompts in comparison to traditional CoT prompting.

A modified version of the MedQA USMLE question dataset was used for this study. Questions were converted to free response by removing the multiple-choice options after the question stem. Only Step 2 and Step 3 USMLE questions were included, as Step 1 questions focus heavily on memorization of facts rather than clinical reasoning skills. Only questions evaluating the task of diagnosing a patient were included to simplify prompt engineering. A training set of 95 questions was used for iterative prompt development and a test set of 518 questions was reserved for evaluation. The full test set can be found in Supplementary Data 1.

GPT-4 performance was also evaluated on the New England Journal of Medicine (NEJM) Case Records series. The NEJM Case Records series is designed as an educational resource for physicians, with each case providing a clinical case description followed by expert analysis of the case with a clinical diagnosis. We included the 310 most recently published cases in this study. Ten cases were excluded because they either did not provide a definitive final diagnosis or exceeded the maximum context length of the GPT-4 API. A full list of all cases included (by title and DOI number) can be found in Supplementary Data 2. For this evaluation, we compared traditional CoT prompting to the highest performing clinical reasoning CoT prompt (differential diagnosis reasoning) on the modified MedQA dataset.

---

### Small language models learn enhanced reasoning skills from medical textbooks [^c0e06a39]. NPJ Digital Medicine (2025). Medium credibility.

Fig. 6
The left panel represents the textbook chunk, while the right panel displays data generated based on that chunk.

Spans highlighted in the same color indicate related content. It is evident that GPT-4 heavily relies on the textbook to generate questions, resulting in a significant reduction in hallucination and ensuring that the generated QA examples cover essential content from the textbook. This leads to an overall improvement in quality.

In addition to the CoT datasets that we constructed, we incorporated existing instruction-following datasets into the model training to enhance the versatility of our model for various medical-domain applications (see Table 2 for the summary). We refined or repurposed several datasets to better suit the model training and align with the target applications. Below are detailed descriptions of each dataset:
MedMCQA: this large dataset comprises exam questions from the two Indian affiliations, AIIMS (All India Institute of Medical Sciences) and NEET PG (National Eligibility cum Entrance Test for Post Graduate courses). We leveraged this dataset because it spans a broad spectrum of medical knowledge across 21 subjects, which could complement the medical knowledge of small LMs. Although the dataset also includes human explanations for the questions, we did not utilize them because they were too brief and not sufficiently detailed.
LiveQA: this dataset contains healthcare-related questions received by the U.S. National Library of Medicine (NLM), accompanied by free-form responses from experts. The questions span various topics including diseases, drugs, and more, making it ideal for training our model on real-world queries.
MedicationQA: this dataset comprises consumer questions, particularly focusing on inquiries related to drugs, along with expert responses. Since these types of questions constitute a significant portion of healthcare inquiries, they serve as valuable resources for developing practical medical AI models.
ChatDoctor-cleaned (ours): the data is derived from ChatDoctor, a collection of real patient inquiries and doctor responses obtained from an online medical consultation platform. While ChatDoctor provides rich and useful data examples, it also contains noise inherent to online Q&A platforms, such as greetings or closing remarks by the doctors (e.g. they often begin the response with "Welcome to Chat Doctor" or end the response with "Best wishes, Chat Doctor."). To address this, we manually created three noisy inputs and corresponding corrected outputs, utilizing them as in-context examples. We then employed GPT-3.5 to remove noise from 112K original responses, resulting in our ChatDoctor-cleaned dataset. See Supplementary Table 8 for the input prompt.
MedQA-dialog (ours): while engaging in multi-turn dialog with users is a crucial requirement for medical AI, there's a lack of suitable training datasets for this purpose. To fill this gap, we instructed GPT-3.5 to generate conversations by role-playing as both patients and doctors based on MedQA questions and corresponding CoT reasoning. In the dialog, the patient should minimally communicate their symptoms and medical history, while the doctor should guide the conversation, asking follow-up questions to gather a thorough medical history and records. We generated 4.8K conversations corresponding to the intended output format from the entire 9.3K MedQA examples, creating the MedQA-dialog dataset. Details of the input prompt is provided in Supplementary Table 9.
MedInstruct-52K: this dataset is a collection of synthetic 52K medical-domain instructions generated by GPT-3.5 and GPT-4, similar to the self-instruct approach. We included this dataset to improve the model's generalizability to various user queries and use cases.

---

### Designing, conducting and reporting clinical research. A step by step approach [^c06e9c42]. Injury (2006). Low credibility.

There are five major steps that one must navigate successfully to take a study idea and turn it into a publication that may have an impact on clinical practice. These steps include developing the study question(s), developing the study plan, implementing the study plan, reporting the results and submitting the manuscript(s) for publication. This review takes each of these steps and expands on its important components. More detail is given for steps one, two and five. Furthermore, the review is augmented with tables and checklists that may serve as tools in the planning and execution of a clinical study. Though it does not address every detail for each of the steps discussed, readers of all experience levels should find it a useful tool in the planning, execution and reporting of their next clinical study.

---

### Great question! the art and science of crafting high-quality multiple-choice questions [^b59efb11]. Journal of the American College of Radiology (2022). Medium credibility.

Assessment of medical knowledge is essential to determine the progress of an adult learner. Well-crafted multiple-choice questions are one proven method of testing a learner's understanding of a specific topic. The authors provide readers with rules that must be followed to create high-quality multiple-choice questions. Common question writing mistakes are also addressed to assist readers in improving their item-writing skills.

---

### Practical guide to the idea, development and exploration stages of the IDEAL framework and recommendations [^1ecdcea6]. The British Journal of Surgery (2016). Low credibility.

Background

Evaluation of new surgical procedures is a complex process challenged by evolution of technique, operator learning curves, the possibility of variable procedural quality, and strong treatment preferences among patients and clinicians. Preliminary studies that address these issues are needed to prepare for a successful randomized trial. The IDEAL (Idea, Development, Exploration, Assessment and Long-term follow-up) Framework and Recommendations provide an integrated step-by-step evaluation pathway that can help investigators achieve this.

Methods

A practical guide was developed for investigators evaluating new surgical interventions in the earlier phases before a randomized trial (corresponding to stages 1, 2a and 2b of the IDEAL Framework). The examples and practical tips included were chosen and agreed upon by consensus among authors with experience either in designing and conducting IDEAL format studies, or in helping others to design such studies. They address the most common challenges encountered by authors attempting to follow the IDEAL Recommendations.

Results

A decision aid has been created to help identify the IDEAL stage of an innovation from literature reports, with advice on how to design and report the IDEAL study formats discussed, along with the ethical and scientific rationale for specific recommendations.

Conclusion

The guide helps readers and researchers to understand and implement the IDEAL Framework and Recommendations to improve the quality of evidence supporting surgical innovation.

---

### Elacestrant (Orserdu) [^25e5bc7d]. FDA (2024). Medium credibility.

The dosage of elacestrant PO for treatment of breast cancer in postmenopausal female adults with ESR1 mutation (advanced or metastatic, ER-positive, HER2-negative, progression after ≥ 1 line of endocrine therapy) is 345 mg PO daily until disease progression or unacceptable toxicity

---

### Towards generalist foundation model for radiology by leveraging web-scale 2D&3D medical data [^d089353e]. Nature Communications (2025). High credibility.

Radiology multimodal dataset (RadMD)

For domain-specific finetuning, we filter out the non-radiology images from MedMD, and construct a clean subset, named Rad iology M ultimodal D ataset (RadMD), dedicating to supervised visual instruction tuning. It contains a total of 3M images, spanning various data formats, modalities, and tasks, featuring over 5000 diseases, as shown in Fig. 7 b.

In general, we have conducted the following filtering process: (i) remove non-radiologic images; (ii) remove the entire PMC-OA and PMC-Inline datasets, as the images in PubMed are 2D-only, thus differ from real clinical cases, additionally, the writing styles between academic papers and real clinical reports are inconsistent; (iii) remove a large portion of 2D image cases from PMC-Series, to emphasize the 3D images in training. (iv) filter out the information about patient age or structure size, as the image spacing and patient background information are not provided. Specifically, we applied string matching techniques using Python's regular expressions to remove any sentences containing terms related to physical measurements, such as "mm", "cm", or decimal numbers (e.g. "2.5 cm"), as these are indicative of missing or incomplete metadata related to patient age, structure size, or image spacing. This step primarily addresses the problem in the report generation tasks, where such metadata would otherwise cause incorrect or unpredictable descriptions.; (v) balance the number of normal and abnormal patients in the diagnosis datasets, as generative models are sensitive to data imbalances. More comprehensive details regarding the filtering process and the resulting dataset sizes can be found in Supplementary Table 3.

---

### Cutting edge or blunt instrument: how to decide if a stepped wedge design is right for you [^471f52f2]. BMJ Quality & Safety (2021). High credibility.

When might I consider doing a stepped wedge trial?

Research designs are shaped as much by practical constraints as by abstract schemes, and it is always a good idea to start with the constraints and work towards a design, rather than start with a design and try to fit it to constraints. These constraints will be unique to each research context, and box 1 lists some areas to think about. Still, there are some common features of settings where a stepped wedge trial might be considered as a possible design, and we now review these.

Box 1
Practical constraints on the design of a longitudinal cluster randomised trial

Are there limits on the time available to complete the evaluation, on the number of clusters, or on the number of participants (or the rate at which you can recruit participants) at each cluster? These constraints put limits on the overall scale of the evaluation, or force trade-offs between different design characteristics.
How will participants and their data be sampled in your study: as a series of cross-sectional surveys, as a continuous stream of incident cases, as a cohort followed over time, or some other way? Does the timescale divide into cycles, seasons or milestones that influence how you will sample participants and data?
Is there a limit on how many clusters can implement the intervention at the same time in the evaluation? If this is constrained by research resources (eg, if there are only enough trained research staff to implement the intervention one cluster at a time) then implementation must be staggered in some way.
If implementation is to be staggered, is there a minimum 'step length'? If the same team delivers the intervention in different clusters at different steps, then bear in mind it may take some time to get the intervention fully operational at a site, and the team will also need time to relocate from one cluster to the next.

---

### Exenatide [^b2968227]. FDA (2025). Medium credibility.

STEP 4 Prepare the Pen

Note: If you do not see liquid after 4 times, see Commonly Asked Questions, number 3, in Section 4 of these Instructions for Use.

STEP 5 Complete New Pen Setup

Section 3 Now that you have done the one-time-only new pen setup, follow Section 3 for all of your injections.

ROUTINE USE

STEP 1 Check the Pen

STEP 2 Attach the Needle

STEP 3 Dial the Dose

Note: If you cannot turn the dose knob away from you to the, see Commonly Asked Questions, number 7, in Section 4 of these Instructions for Use.

STEP 4 Inject the Dose

Note: If you see several drops of Exenatide Injection leaking from the needle after the injection, you may not have received a complete dose. See Commonly Asked Questions, number 4, in Section 4 of these Instructions for Use.

STEP 5 Remove and Dispose of the Needle

STEP 6 Store Pen for Next Dose

a. Replace Blue Pen Cap on pen before storage.

b. Store your Exenatide Injection Pen at a temperature between 36° to 77°F (2° to 25°C). (See Storing Your Exenatide Injection Pen in Section 1 of these Instructions for Use for complete storage information.)

---

### VA / DoD clinical practice guideline for the management of chronic obstructive pulmonary disease [^ea771590]. VA/DoD (2021). High credibility.

Respimat inhalers — first time use preparation and priming are detailed as follows: Step 1, "Press down on the safety catch and firmly pull off the clear base with the other hand." Step 2, "Write the discard by date on the label; the discard by date is 3 months from the date the cartridge is inserted into the inhaler." Step 3, "Insert the narrow end of the cartridge into the inhaler, pressing down on a firm surface; about 1/8 of an inch will remain visible when the cartridge is correctly inserted; do not remove the cartridge once it has been inserted into the inhaler." Step 4, "Click the clear base back into place; do not remove the clear base again." For priming, the guidance states: "It is important to follow these steps to ensure the dosing system is filled for first time use. Priming is necessary to make sure the correct amount of medicine is delivered. It will not affect the number of doses available."

---

### NCCN guidelines® insights: thyroid carcinoma, version 1.2025 [^7200129c]. Journal of the National Comprehensive Cancer Network (2025). High credibility.

NCCN Thyroid Carcinoma — Version 1.2025 updates on postoperative thyroglobulin (Tg) and radioiodine (RAI) use indicate that RAI not typically recommended (if all present) includes Postoperative unstimulated Tg < 1 ng/mL or stimulated Tg < 2 ng/mL, while RAI selectively recommended (if any present). The updates also remove pathways/imaging steps including Progressively rising Tg (basal or stimulated), pathway removed (also for FOLL-8), Upper pathway, column 6, bullet removed: Post-treatment iodine-131 imaging (whole body RAI scan), and Unresectable, RAI uptake present, upper and lower pathway, bullet removed: Post-treatment iodine-131 whole body imaging.

---

### Autonomous medical evaluation for guideline adherence of large language models [^da0809ca]. NPJ Digital Medicine (2024). Medium credibility.

Discussion

The AMEGA benchmark introduces a novel approach for evaluating the adherence of LLMs to medical guidelines. The benchmark distinguishes itself from existing methods by employing an open-ended question-answering format that closely mimics real-world clinical interactions and emphasizes iterative response refinement. This approach enables a comprehensive assessment of LLMs' ability to provide detailed and nuanced responses, taking into account the complexity of medical decision-making.

Existing general LLM benchmarks, such as SuperGLUEand HELM (Holistic Evaluation of Language Models), offer broad insights into language model performance through metrics like accuracy, F1 score, precision, and recall. These benchmarks evaluate models on tasks ranging from reasoning and factual recall to advanced language understanding, providing an overview of LLM capabilities across different domains. Additional benchmarks like MMLU (Massive Multitask Language Understanding), SQuAD, CoQA (Conversational Question Answering), and DROP (Discrete Reasoning Over the content of Paragraphs)assess models' ability to engage in question-answering tasks that also require reasoning, factual recall, and problem-solving. Benchmarks focusing on commonsense understanding, such as HellaSwag, and problem-solving, like GSM8K (Grade School Math 8K), further evaluate LLMs' capabilities across various tasks.

---

### Exenatide [^a44dacd5]. FDA (2025). Medium credibility.

Section 2 Read and follow the directions in this section only after you've read Section 1 — What You Need To Know About Your Exenatide Injection Pen.

GETTING STARTED

Set up your new pen just before you use it the first time. For routine use, do not repeat this one-time-only new pen setup. If you do, you will run out of Exenatide Injection before 30 days of use.

ONE-TIME-ONLY NEW PEN SETUP

STEP 1 Check the Pen

STEP 2 Attach the Needle

STEP 3 Dial the Dose

Note: If you cannot turn the dose knob away from you to the, see Commonly Asked Questions, number 7, in Section 4 of these Instructions for Use.

STEP 4 Prepare the Pen

Note: If you do not see liquid after 4 times, see Commonly Asked Questions, number 3, in Section 4 of these Instructions for Use.

STEP 5 Complete New Pen Setup

Section 3 Now that you have done the one-time-only new pen setup, follow Section 3 for all of your injections.

ROUTINE USE

STEP 1 Check the Pen

STEP 2 Attach the Needle

STEP 3 Dial the Dose

Note: If you cannot turn the dose knob away from you to the, see Commonly Asked Questions, number 7, in Section 4 of these Instructions for Use.

---

### Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs [^4b3e6cbe]. The Journal of Allergy and Clinical Immunology: In Practice (2020). High credibility.

Paclitaxel desensitization — two-bag/8-step protocol: Under the same paclitaxel infusion context, the two-bag example lists Solution 1 as 250 mL at 0.118 mg/mL with 18.75 mL infused (dose 2.213 mg) and Solution 2 as 250 mL at 1.167 mg/mL with 250 mL infused (291.787 mg). Step examples shown include step 1 using solution 1 at 5 mL/h for 15 min with 1.25 mL infused (0.148 mg; cumulative 0.148 mg) and step 4 using solution 1 at 40 mL/h for 15 min with 10 mL infused (1.18 mg; cumulative 2.213 mg).

---

### How to find answers to clinical questions [^7cb7fcd9]. American Family Physician (2009). Low credibility.

Many barriers exist to finding answers to physicians' clinical questions. Lack of time, resources, and computer skills, as well as physicians' environment and attitudes about problem solving, all contribute to unanswered questions. Making use of computer-based information resources can give physicians a framework for answering questions and keeping their practice consistent with the best available evidence.

---

### Patient perceptions and preferences for a mealtime insulin delivery patch [^6b262d15]. Diabetes Therapy (2018). Low credibility.

Participant Training for Use of the Study Device

Prior to the simulated-use period, participants received training by a human-factors engineer ("the trainer"), who followed a training protocol developed with a diabetes educator. Patients were trained following the step-by-step instructions outlined in the standard mealtime insulin-delivery system quick-start guide that is provided with the product. After this demonstration, participants completed a comprehension test of the instructions for the tasks of opening the packaging, filling the device, priming the device, applying the device, dosing, and removing the device in an open-book test format. Participants then conducted a practice setup and use demonstration under supervision of the trainer and were asked a series of questions to ensure their understanding and safe use of the patch at home. In addition, all participants received the standard mealtime insulin-delivery system user guide (provided with the product) containing complete instructions, including all warnings, frequently asked questions, and troubleshooting tips. Participants were advised to carefully read the user guide before beginning to use the patch.

---

### Global strategy for asthma management and prevention [^e928504b]. GINA (2024). High credibility.

Track 2 (alternative) for adults and adolescents using SABA reliever outlines treatment Steps 1–4 with specified controller options and a referral step, with caution about adherence. Step 1 states "Take ICS whenever SABA taken*," Step 2 is "Low dose maintenance ICS," Step 3 is "Low dose maintenance ICS-LABA," Step 4 is "Medium/high dose maintenance ICS-LABA," and Step 5 is "Refer for expert assessment, phenotyping, and add-on treatment for severe asthma"; the reliever is "as-needed ICS-SABA*, or as-needed SABA." It notes that "This is an alternative approach if Track 1 is not possible, or if a patient's asthma is stable with good adherence and no exacerbations on their current therapy," and advises "before prescribing a regimen with SABA reliever, consider whether the patient is likely to be adherent with their maintenance therapy; if not, they will be at higher risk of exacerbations." Abbreviations are defined on-page as "ICS: inhaled corticosteroid; LABA: long-acting beta agonist; SABA: short-acting beta2 agonist."

---

### Tutorials in clinical research: part III. selecting a research approach to best answer a clinical question [^cba05e30]. The Laryngoscope (2001). Low credibility.

Objective

This is the third in a series of sequential "Tutorials in Clinical Research". The objectives of this specific report are to enable the reader to rapidly dissect a clinical question or article to efficiently determine what critical mass of information is required to answer the question and what study design is likely to produce the answer.

Study Design

Tutorial.

Methods

The authors met weekly for 3 months exploring clinical problems and systematically recording the logic and procedural pathways from multiple clinical questions to the selection of proper research approaches. The basic elements required to understand the processes of selection were catalogued and field tested, and a report was produced to define and explain these elements.

Results

Fundamental to a research approach is the assembly of subjects and the allocation of exposures. An algorithm leading to the selection of an approach is presented. The report is organized into three parts. The tables serve as a rapid reference section. The initial two-part narrative explains the process of approach selection. The examples section illustrates the application of the selection algorithm.

Conclusions

Selecting the proper research approach has six steps: the question, logic and ethics, identification of variables, data display considerations, original data source considerations, and selection of prototypical approaches for assembly of subjects. Field tests of this approach consistently demonstrated its utility.

---

### Curriculum development: a how to primer [^55349fb6]. Family Medicine and Community Health (2019). Medium credibility.

Step 1. Needs assessment/statement

The needs assessment helps us answer 'Why'? In the case of curriculum development, the answer may be quite broad and should point to the distinction between the current teaching strategy surrounding a learning need and what should be changed about it. At the start, it is wise to consider whose needs are the priority. This may start with a learner's needs (either attitudinal and knowledge-based needs, readiness to learn or timing), but likely extends to the patients and communities for whom the learner will be caring. When justifying time or funding, an articulation of how this curriculum might meet regulatory or board requirements can be useful.

The mechanics of a needs assessment includes readily available information and the collection of new information. The acquisition of new information can be structured (survey or medical knowledge assessment), semi-structured (series of discussions or a call to action based on sentinel event), research/data driven (data on learners' performance or clinical quality data) or based on regulatory requirements.

A very basic example (see table 1), experienced by one of the authors was the identification of a gap in knowledge leading to the development of a newly structured educational activity.

Once the needs assessment is finalised, and the needs have been articulated, a rationale statement should be agreed on. This rationale statement is 1–3 lines that articulates the fundamental findings from the needs assessment to guide the development of the curriculum. The rationale statement can then be used to keep the curriculum on task. It is intended to be modified only if there is a serious oversight in the development. In this way, the needs assessment and rationale statement can truly render a solid foundation for the curriculum in development.

Step 2. Determining and prioritising content

This is the first step in beginning to articulate what is going to be included, a general description of the content, along with a prioritisation of that content. In the example of the communication skills curriculum referenced above, the content was determined both by working backwards from the milestone goals and also from reviewing what experts in the field have identified. In some cases, there will not be expert knowledge or milestones to work from, and in these cases, original research might be needed, such as surveys of experts in the field, or analysis of conversation around a difficult topic needing to be addressed. An example of this last strategy can be seen in a recent publication on addressing the topic of racism in medical education (see table 1).

---

### Improving the workflow of nursing assistants at a general hospital in Japan [^011025b6]. BMJ Open Quality (2017). Medium credibility.

Design

We used the Model For Improvement to define the problem, aim and measurements of our intervention according to the model's three questions: (1) 'what are we trying to accomplish?', (2) 'how will we know a change is an improvement?' and (3) 'what changes can we make that will result in an improvement?'

For our intervention, we used the TEAMS–BP (Training for Effective & Efficient Action in Medical Service–Better Process) work improvement method.TEAMS–BP was developed at the University of Tsukuba in 2012 with the co-operation of the Japan Industrial Training Association. It is based on the Japanese Training Within Industry–Job Method (TWI–JM). As shown in online supplementary appendix 1, TEAMS–BP consists of four steps. Work improvement is carried out using the task breakdown sheet (online supplementary appendix 2 and supplementary appendix 3). Although TEAMS–BP differs from TWI–JM in presentation, programme lectures and format, the basic concept of the four steps is the same.

Step 1

Break down the task: the nursing assistants' task was broken down in detail and recorded on the task breakdown sheet. Several nursing assistants helped our team break down the task through careful onsite observations. Differences in how the task was conducted among nursing assistants were also noted.

Step 2

Evaluate every detailed step: once the tasks were detailed, wasteful tasks were identified and eliminated. We discussed each task as a team according to six basic questions (who, what, where, why, when and how?) and recorded the answers to these questions in the ideas column of the task breakdown sheet.

Step 3

Develop a new process: our team developed a new process when we analysed the answers generated in Step 2. Task details were individually evaluated according to the following actions, in order of eliminate, combine, rearrange and simplify. If the task detail could be eliminated, this was a 100% improvement and no further investigation was required.

---

### VA / DoD clinical practice guideline for the management of chronic obstructive pulmonary disease [^163a4279]. VA/DoD (2021). High credibility.

Dry powder inhaler (DPI) use — how to correctly use a dry powder inhaler is described as follows: Step 1: Open, load, and hold the inhaler following the manufacturer's directions. Step 2: Sitting or standing up straight, take a deep breath and breathe out completely. Step 3: Bring the inhaler to the mouth; seal lips tightly around the mouthpiece and breathe in quickly and deeply through the inhaler for about 3 to 5 seconds. Step 4: Remove the inhaler from the mouth and hold your breath for a count of 10 seconds, or as long as able to comfortably with mouth closed. Step 5: Breathe out slowly away from the inhaler. Repeat the steps above for each inhalation, waiting at least 60 seconds between puffs. Step 6: Close the inhaler and store in a cool, dry and safe place. Cleaning and aftercare instructions include do not wash with soap and water; to clean, wipe mouthpiece with a dry cloth at least once a week or as needed; and always rinse mouth with water, swishing and gargling, and spit out after using inhaled corticosteroids; do not swallow.

---

### Timolol maleate ophthalmic gel forming solution [^2e1dc6a2]. FDA (2023). Medium credibility.

 Step 3. Remove the Timolol Maleate Ophthalmic Gel Forming Solution cap by turning the cap in the direction of the arrows shown (See Figure A). Put the cap in a clean and dry area. Do not let the tip of the bottle touch your fingers or other surfaces.

Figure A

 Step 4. Hold the bottle between your thumb and index finger with 1 hand. Use the index finger of the other hand to pull down the lower eyelid to form a pocket for the eye drop (See Figure B). Tilt your head backwards.

Figure B

 Step 5. Place the tip of the bottle close to your eye. Be careful not to touch your eye with the tip of the bottle. Gently squeeze the bottle and let 1 drop fall into the space between your lower eyelid and your eye (See Figure C). If a drop misses your eye, follow the instructions in steps 4 and 5 again.

Figure C

 Step 6. If your doctor has told you to use Timolol Maleate Ophthalmic Gel Forming Solution in both eyes, repeat steps 4 and 5 for your other eye.

 Step 7. Put the cap back on the bottle and close.

- The Timolol Maleate Ophthalmic Gel Forming Solution bottle tip is made to give 1 drop at a time. Do not try to make the hole in the tip of your bottle bigger.

---

### Glucagon injection (gvoke vialDx) [^e614a6d7]. FDA (2025). Medium credibility.

Important Warnings

Do not open pouch until time of use.
Do not use after the expiration date has passed.
Do not use if the needle cap has been removed or is damaged.
Do not remove the needle cap until you are ready to inject.
Do not remove the finger flange from the syringe.
Call a healthcare provider as soon as GVOKE® PFS has been injected.
If the patient does not wake up within 15 minutes, give another dose of GVOKE PFS and call for emergency medical help right away.
Feed the patient as soon as he or she wakes up and is able to swallow.

Read and become familiar with the following instructions before an emergency happens. If you have questions about using GVOKE PFS, talk with your healthcare provider or pharmacist.

3. PREPARING TO INJECT GVOKE® PFS

Step 1. Remove GVOKE PFS from Foil Pouch

Tear open pouch at the dotted line and carefully remove GVOKE PFS (see Figure 1).

Figure 1

Step 2. Check the Expiration Date

Check the expiration date printed on the label of GVOKE PFS (see Figure 2).
Important: Do not use GVOKE PFS if the expiration date has passed. If GVOKE PFS is expired, throw it away in an FDA cleared sharps container and use a new GVOKE PFS.

---

### 2019 methodology for creating expert consensus decision pathways: a report of the American college of cardiology [^7f0b4e46]. Journal of the American College of Cardiology (2019). High credibility.

Expert Consensus Decision Pathway timeline and scope — The timeline for development is more compressed than a Clinical Practice Guideline, usually in the range of 8 to 12 months, during which time the Work Group tracks emerging evidence and incorporates it into the pathway. Determination of the scope is a critical early step, and the Work Group should keep the scope wide enough to provide guidance on the most important clinical questions yet not so broad as to be unmanageable within the narrow timeframe typically allotted for content development.

---

### A summary of the methods that the national clinical guideline centre uses to produce clinical guidelines for the national institute for health and clinical excellence [^17347588]. Annals of Internal Medicine (2011). Medium credibility.

NICE study search and retrieval workflow — Search results undergo a First sift: titles (done by information scientist or systematic reviewer) to exclude studies outside the topic; a Second sift: abstracts (done by systematic reviewer) to exclude studies that are not relevant to the review questions; and Assessment of full articles (done by systematic reviewer) to exclude studies on limits set by the GDG (for example, study design or outcomes), after which studies included proceed for data extraction; because of potential bias or error, a second reviewer performs sampling checks, and usually several thousand titles are sifted at the first stage.

---

### Standards of care in diabetes – 2025 [^5eb43e21]. Diabetes Care (2025). High credibility.

Regarding follow-up and surveillance for diabetes mellitus type 1, more specifically with respect to continuous glucose monitoring, ADA 2025 guidelines recommend to implement early continuous glucose monitoring in adult patients with T1DM to improve glycemic outcomes and QoL and minimize hypoglycemia.

---

### Getting started in primary care research: choosing among six practical research approaches [^388e1e15]. Family Medicine and Community Health (2019). Medium credibility.

Recording details of clinical stories

Let us now review how the case above served as a starting point for developing a research question, and how we can replicate the process of question development and choice of method using other stories. Look at table 3 and note the steps to follow. Then retrieve and use your list of clinical stories to generate a research question. Using full sentences if possible, complete the other sections of the table. Record when the event occurred, especially specific date in the event of a need to review records. Indicate who was involved, for example, specific patient, learner or administrative personnel. Record in detail what happened. Indicate where the event occurred, for example, ambulatory setting, hospital and so on. Record why the care, incident or phenomenon was perceived to be a problem. Describe how the problem was responded to, and as relevant, the outcome of the response/intervention. Use the comment section to record any other information that might be important, including ideas or other reminders that might be helpful at a later time, for example, others involved, follow-up issues and so on.

Analogies between clinical practice and conducting clinical, management and education research

The five major steps of the approach to research enquiry are remarkably similar to the care of patients (see table 4). Practitioners new to research may found this analogy helpful for thinking about the research process.

Table 4
Five similar steps in the process of clinical care, and conducting clinical, management and educational research

'Trying On' feasible research approaches

Having identified topics of interest, emerging researchers often become stuck at the fourth step in table 4. As they are uncertain about what approach to use, it is hard to identify and settle on a strategy for intervention and/or research. I advise 'trying on' a variety of options. This means considering the various research approaches, thinking through the work involved and the expected outcomes. Think of the analogy of trying on different clothes to find out what is the best 'fit'. This article now focuses on 'trying on' the six different approaches featured in this special issue of FMCH.

---

### Pegfilgrastim (Neulasta) [^afd37669]. FDA (2025). Medium credibility.

Patient INSTRUCTIONS FOR USE

Neulasta®Onpro®(nu-las-tah)

(pegfilgrastim) injection

Single-Use On-body Injector

AMGEN

Neulasta ®

(pegfilgrastim)

 Onpro ®

kit

Contents

A healthcare provider who is familiar with Neulasta should answer your questions. For general questions or support call 1-844-MYNEULASTA (1-844-696-3852) or visit www.neulasta.com.

Step 1: Monitor On-body Injector

Step 2: Observe Dose Delivery

Step 3: Verify Dose Complete

Step 4: Finish

Frequently Asked Questions

How do I know it is safe to remove the on-body injector?

It is safe to remove the on-body injector after checking the following:

FAQ

What to do if you hear beeping or when you look at the status light and it is flashing red?

If the status light is flashing red, you may not have received your full dose and may need a replacement dose. Call your healthcare provider right away.

What do I do if the on-body injector comes off before the full dose is delivered?

Call your healthcare provider right away if the on-body injector at any time comes away from your skin before your full dose delivery, as you may need a replacement dose. Do not reapply it.

What if there is blood at my application site after the on-body injector has been removed?

If there is blood, press a clean cotton ball or gauze pad on the application site. Apply an adhesive bandage if needed.

What if my application site is red or tender after on-body injector removal?

Call your healthcare provider right away if you experience persistent or worsening redness or tenderness at the application site, as this can be a sign of infection.

Notes

Neulasta Onpro

Patient INSTRUCTIONS FOR USE

Neulasta®(pegfilgrastim)

Manufactured by:

Amgen Inc.

One Amgen Center Drive

Thousand Oaks, California 91320–1799

US License No. 1080

Patent: http://pat.amgen.com/onpro/

© 2002 to 2025 Amgen Inc. All rights reserved.

http://www.neulasta.com

1-844-MYNEULASTA (1-844-696-3852)

Revised: 11/2020

V10

---

### Technical update on HIV-1 / 2 differentiation assays [^50eb7933]. CDC (2016). Medium credibility.

HIV-1/HIV-2 differentiation testing — alternatives when the FDA-approved antibody differentiation immunoassay cannot be used states that there may be circumstances under which a laboratory is unable to adopt the FDA-approved HIV-1/HIV-2 antibody differentiation immunoassay, and in this situation a laboratory has alternatives for that step in the algorithm, some of which could delay turnaround time for test results. Send specimens to another laboratory that offers the FDA-approved supplemental HIV antibody differentiation assay. Refer to CDC/APHL laboratory testing guidance section I, "Alternative Testing Sequences When Tests in the Recommended Algorithm Cannot be Used".

---

### Patient satisfaction measurement in occupational and environmental medicine practice [^1bb97065]. Journal of Occupational and Environmental Medicine (2018). Medium credibility.

Appendix 1: Patient Satisfaction Measurement in Occupational and Environmental Medicine (OEM) practice — Patient Satisfaction Survey provides a patient experience instrument with visit-type routing and clinic/provider items. Patients select why they came (Work-related injury; Referral from another health care provider; Work Exams; Other Examinations; Medical Testing Only) and are directed as follows: for the first two categories, "Please answer questions 2–21"; for Work Exams and Other Examinations, "Please answer questions 2–12 and 16–21"; for Medical Testing Only, "Please answer questions 2–7 and 16–21," with the instruction, "If you marked 'Medical Testing Only' in question #1 above, please skip to question #16. Otherwise go to #8." Clinic items include "This clinic was COMFORTABLE" and "I would RECOMMEND this clinic to co-workers for worker health needs," with a follow-up prompt, "If you chose 'Disagree' or 'Strongly Disagree,' please explain why you wouldn't recommend this clinic to coworkers." Provider items include "My doctor was ON TIME for my exam or I was told why the doctor was late" and "My doctor treated me with COURTESY and RESPECT."

---

### Apomorphine hydrochloride (Onapgo) [^777f3899]. FDA (2025). Medium credibility.

Ending the Infusion

The infusion will run for the programmed amount of time, or it can be ended early.

Note: If the plastic cartridge holder detaches from the glass drug cartridge when removing, continue to remove the plastic cartridge holder. Set aside the plastic cartridge holder and remove the glass drug cartridge by pulling it up and off the pump. Continue to Step 13.11.

Disconnecting in an Emergency

If you are having a medical emergency, follow the steps below to disconnect from the pump.

Disposal

At the end of the expected life of the pump, contact Customer Support at 1-833-3ONAPGO (1-833-366-2746) for information and instructions about safe pump disposal.

Cleaning and Disinfecting the Pump

The Pump is a reusable device and should be cleaned and disinfected whenever you see any traces of dirt.

Follow the instructions below and on the following pages for cleaning and disinfecting the pump.

Replacing the Battery

Always have a replacement lithium CR 123A battery available for use.

To replace the battery, follow these steps:

Alarms and Troubleshooting

An error code will display on the screen if there is something wrong with the pump. You will hear a beep when there is an error code, and the LED next to the screen may light up. The table below gives an overview of the possible error codes that may happen, what they mean, and what to do to fix them.

---

### Somatropin (Humatrope) [^e8b8c7b0]. FDA (2025). Medium credibility.

Step 3E – Store Pen and Cartridge for next use

See, " How do I store HumatroPen 6 mg?" in Section 1 of this Instructions for Use for more information.
When it is time for the next scheduled dose, go to Section 3, and repeat Steps 3A through 3D.
When using the Hidden Needle Cover with HumatroPen 6 mg, repeat steps 1 to 10 of the Hidden Needle Cover Instructions for Use.

Commonly asked questions:

Do I need to perform the New Cartridge Setup before every dose?
No. You only need to perform the New Cartridge Set-up 1 time for each Cartridge, just before a new Cartridge is used for the first time.
The purpose of the New Cartridge Set-up is to make sure the HumatroPen 6 mg with an attached HUMATROPE 6 mg Cartridge are ready to use.
If you repeat the New Cartridge Set-up before each routine dose, you may run out of HUMATROPE early. The small amount of medicine used in the New Cartridge Set-up will not affect the amount of HUMATROPE in the Cartridge.
What should I do if the Cartridge label and Pen do not match?
Do not use the Pen if the Cartridge strength on the HUMATROPE Cartridge label does not match the number on the Pen's front housing. This is important to make sure the correct dose of HUMATROPE is given.
Contact your healthcare provider for a replacement.
What should I do if the HUMATROPE is not clear?
Do not use the Pen if the liquid is cloudy or contains particles. Contact your healthcare provider or call Lilly at 1-800-545-5979 or go to www.humatrope.com.
Why are there air bubbles in the Cartridge?
Air bubbles may remain in the Cartridge after mixing.
If the Pen is stored with a Needle attached, air bubbles may form in the Cartridge.

---

### A primer on selected aspects of evidence-based practice relating to questions of treatment. part 1: asking questions, finding evidence, and determining validity [^0f9513a7]. The Journal of Orthopaedic and Sports Physical Therapy (2008). Low credibility.

The process of evidence-based practice (EBP) guides clinicians in the integration of individual clinical expertise, patient values and expectations, and the best available evidence. Becoming proficient with this process takes time and consistent practice, but should ultimately lead to improved patient outcomes. The EBP process entails 5 steps: (1) formulating an appropriate question, (2) performing an efficient literature search, (3) critically appraising the best available evidence, (4) applying the best evidence to clinical practice, and (5) assessing outcomes of care. This first commentary in a 2-part series will review principles relating to steps 1, 2, and 3 of this 5-step model. The purpose of this commentary is to provide a perspective to assist clinicians in formulating foreground questions, searching for the best available evidence, and determining validity of results in studies of interventions for orthopaedic and sports physical therapy.

---

### Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs [^444379cb]. The Journal of Allergy and Clinical Immunology: In Practice (2020). High credibility.

β-Lactam desensitization (intravenous protocol) — for a target dose of 1 g, an example protocol uses three solutions each with 250 mL diluent at drug concentrations of 0.04, 0.4, and 4 mg/mL, and escalates infusion steps to deliver a cumulative dose of 1000 mg over a total infusion time of 337.9 min; the final step uses solution 3 at 80 mL/h for 172.9 min administering 922.13 mg.

---

### Standards of care in diabetes – 2025 [^31be65a6]. Diabetes Care (2025). High credibility.

Regarding diagnostic investigations for hypoglycemia, more specifically with respect to screening for cognitive impairment, ADA 2025 guidelines recommend to simplify diabetes treatment plans as much as possible for patients with cognitive impairment and tailor to minimize the risk of hypoglycemia.

---

### 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-thoracic Surgery (EACTS) [^f5d8a338]. European Heart Journal (2024). High credibility.

Regarding surgical interventions for atrial fibrillation, more specifically with respect to LAA closure, indications, EACTS/ESC 2024 guidelines recommend to consider performing surgical closure of the LAA as an adjunct to oral anticoagulation in patients with AF undergoing endoscopic or hybrid AF ablation to prevent ischemic stroke and thromboembolism.

---

### Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs [^410cce7d]. The Journal of Allergy and Clinical Immunology: In Practice (2020). High credibility.

Aspirin desensitization for patients without aspirin-exacerbated respiratory disease (AERD) provides two oral options. Option 1 uses dose escalation every 15–30 min until the target daily dose has been tolerated with Day 1 steps 0 1, 15 2, 30 5, 45 10, 60 20, 75 40, and 90 81. Option 2 repeats the dose every 90 min until no further reaction symptoms with Day 1 steps 0 40.5, 90 40.5, and 180 Repeat 40.5 only if patient reacts. A footnote adds: On subsequent days, start aspirin 81 mg daily.

---

### Standards of care in diabetes – 2025 [^d4969f8c]. Diabetes Care (2025). High credibility.

Regarding diagnostic investigations for diabetes mellitus type 1, more specifically with respect to screening for PAD, ADA 2025 guidelines recommend to assess lower extremity pulses, capillary refill time, rubor on dependency, pallor on elevation, and venous filling time for initial screening of PAD. Obtain ankle-brachial index with toe pressures and further vascular assessment as appropriate in patients with symptoms of claudication or decreased or absent pedal pulses.

---

### Urethral stricture disease guideline amendment (2023) [^f6f8fc47]. The Journal of Urology (2023). High credibility.

Regarding follow-up and surveillance for urethral stricture, more specifically with respect to follow-up, AUA 2023 guidelines recommend to obtain monitoring for symptomatic recurrence after urethral dilation, direct visual internal urethrotomy, or urethroplasty.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^fbb083b3]. Circulation (2024). High credibility.

Regarding surgical interventions for atrial fibrillation, more specifically with respect to LAA closure, indications, ACC/ACCP/AHA/HRS 2024 guidelines recommend to perform surgical LAA exclusion, in addition to continued anticoagulation, to reduce the risk of stroke and systemic embolism in patients with AF undergoing cardiac surgery with a CHA2DS2-VASc score ≥ 2 or equivalent stroke risk.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^1156111f]. Circulation (2024). High credibility.

Regarding surgical interventions for atrial fibrillation, more specifically with respect to LAA closure, indications, ACC/ACCP/AHA/HRS 2024 guidelines recommend to insufficient evidence to recommend surgical LAA exclusion without continued anticoagulation to reduce the risk of stroke and systemic embolism in patients with AF undergoing cardiac surgery with CHA2DS2-VASc score ≥ 2 or equivalent stroke risk.

---

### METOPROLOL-metoprolol tartrate injection… [^4b069937]. FDA (DailyMed) (2025). Medium credibility.

10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12. 1 Mechanism of Action
12. 2 Pharmacodynamics 12. 3 Pharmacokinetics
12. 5 Pharmacogenomics 13 NONCLINICAL TOXICOLOGY 13. 1 Carcinogenesis, Mutagenesis, Impairment of Fertility.
5. 4 Pheochromocytoma If metoprolol tartrate is used in the setting of pheochromocytoma, it should be given in combination with an alpha blocker, and only after the alpha blocker has been initiated. Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.
7. 4 Digitalis, Clonidine, and Calcium Channel Blockers and Other Drugs that Decrease Heart Rate Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate.

Concomitant administration of beta-blockers with these and other drugs known to decrease heart rate such as sphingosine-1-phosphate receptor modulators may result in additive heart rate lowering effects. Heart failure and shock: May be treated when appropriate with suitable volume expansion, injection of glucagon, intravenous administration of adrenergic drugs such as dobutamine, with α1 receptor agonistic drugs added in presence of vasodilation. Bronchospasm: Can usually be reversed by bronchodilators.
12. 2 Pharmacodynamics When the drug was infused over a 10-minute period, in normal volunteers, maximum beta blockade was achieved at approximately 20 minutes. Equivalent maximal beta-blocking effect is achieved with oral and intravenous doses in the ratio of approximately 2. 5:

1. There is a linear relationship between the log of plasma levels and reduction of exercise heart rate.

Patients were randomized and treated as soon as possible after their arrival in the hospital, once their clinical condition had stabilized and their hemodynamic status had been carefully evaluated. Subjects were ineligible if they had hypotension, bradycardia, peripheral signs of shock, and/or more than minimal basal rales as signs of congestive heart failure.

---

### Standards of care in diabetes – 2025 [^27c0974d]. Diabetes Care (2025). High credibility.

Regarding specific circumstances for diabetes mellitus type 1, more specifically with respect to pediatric patients (physical activity), ADA 2025 guidelines recommend to advise physical activity in all young patients with T1DM with the goal of 60 minutes of moderate- to vigorous-intensity aerobic activity daily, with vigorous muscle-strengthening and bone-strengthening activities at least 3 days per week.

---

### Standards of care in diabetes – 2025 [^1e25a6d5]. Diabetes Care (2025). High credibility.

Regarding nonpharmacologic interventions for diabetes mellitus type 1, more specifically with respect to physical activity, ADA 2025 guidelines recommend to advise most adult patients T1DM to engage in ≥ 150 minutes of moderate- to vigorous-intensity aerobic activity per week, spread over at least 3 days/week, with no more than 2 consecutive days without activity. Consider advising shorter durations (minimum 75 min/week) of vigorous-intensity or interval training for more physically fit patients.

---

### TADALAFIL… [^ee966e6c]. FDA (DailyMed) (2025). Medium credibility.

8. 6 Hepatic Impairment
8. 7 Renal Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12. 1 Mechanism of Action
12. 2 Pharmacodynamics 12. 3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY. once daily use is not recommended. Benign Prostatic Hyperplasia and Erectile Dysfunction/Benign Prostatic Hyperplasia Creatinine clearance 30 to 50 mL/min: A starting dose of 2. 5 mg is recommended. tablet and "U" on other side of tablet. Tadalafil Tablets USP, 10 mg Light orange colored, almond shaped film coated tablets, debossed with "288" on one side of the tablet and "U" on other side of tablet. Tadalafil Tablets USP, 20 mg Yellow color, almond shaped tablets film coated tablets debossed with "289" on one side. degree of cardiac risk associated with sexual activity. Therefore, treatments for erectile dysfunction, including Tadalafil, should not be used in men for whom sexual activity is.

pain after taking Tadalafil should seek immediate medical attention. Patients with left ventricular outflow obstruction, can be sensitive to the action of vasodilators, including.

1. 06,
4. 34). A similar study reported a consistent result, with a risk estimate of 2.
27. Other risk factors for NAION, such as the presence of "crowded" optic disc, may have contributed to the occurrence of NAION in these studies. ability to influence clearance by dialysis, Tadalafil for once daily use is not recommended in patients with creatinine clearance less than 30 mL/min. In patients with creatinine clearance 30–50 mL/min, start dosing at 2. 5 mg once daily, and increase the dose to
5.

Tadalafil for Use as Needed for ED In eight primary placebo-controlled clinical studies of 12 weeks duration, mean age was 59 years a.

---

### Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an endocrine society clinical practice guideline [^a3dbec73]. The Journal of Clinical Endocrinology and Metabolism (2016). Medium credibility.

Regarding follow-up and surveillance for diabetes mellitus type 1, more specifically with respect to continuous glucose monitoring, ES 2016 guidelines recommend to provide education, training, and ongoing support to help achieve and maintain individualized glycemic goals in adult patients with T1DM using continuous subcutaneous insulin infusion and continuous glucose monitoring.

---

### Estradiol (Estradiol vaginal inserts) [^b4022de9]. FDA (2025). Medium credibility.

INSTRUCTIONS FOR USE

Estradiol (es″ tra dye′ ol) Vaginal Inserts, USP

Read this Instructions for Use before you start using estradiol vaginal inserts and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment.

 How should I use estradiol vaginal inserts?

Estradiol vaginal insert is an insert for use only in the vagina. Do not take by mouth.
Wash and dry your hands well before handling estradiol vaginal inserts.

Step 1: Tear off 1 applicator.

Step 2: Pull apart the plastic wrap and remove the applicator (see Figure A).

If after opening the package you see that the estradiol vaginal insert has come out of the applicator but has not fallen out of the package, carefully put the insert back into the applicator for insertion.

Step 3: Hold the applicator between your thumb and middle finger. Leave your index (pointer) finger free to press the applicator plunger (see Figure B).

Step 4: Select the best position for vaginal insertion of estradiol vaginal inserts that is most comfortable for you. For insertion in the lying down position, see Figure C. For insertion in the standing position, see Figure D.

---

### Colorectal cancer screening and prevention [^390b568a]. American Family Physician (2025). High credibility.

Regarding screening and diagnosis for colon cancer, more specifically with respect to indications for screening, high-risk individuals, family history, AAFP 2025 guidelines recommend to obtain CRC screening in patients with ≥ 1 first-degree relatives with CRC or adenomatous polyps, starting at 40 years of age or 10 years before the age of the youngest relative at the time of their diagnosis.

---

### Clotrimazole [^b5a7188a]. FDA. Low credibility.

The dosage of clotrimazole OTIC for treatment of otomycosis in adults is 1 vial OTIC BID for 14 days (1%/0.17 mL)

---

### 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes [^24784e3d]. European Heart Journal (2023). High credibility.

Regarding medical management for diabetes mellitus type 2, more specifically with respect to prevention of CVD, glucose-lowering medications, ESC 2023 guidelines recommend to consider initiating metformin to reduce cardiovascular risk in patients with T2DM without ASCVD or severe target-organ damage at low, moderate,
high, or very high risk.

---

### Imlunestrant [^7b5c5001]. FDA. Low credibility.

Labeled indications for Imlunestrant include:

- Treatment of breast cancer in female adults with ESR1 mutation (advanced or metastatic, ER-positive, HER2-negative, progression after ≥ 1 line of endocrine therapy)

---

### Clarifications to the VSP 2011 operations manual. December 2013 revision [^93e94a23]. CDC (2013). Medium credibility.

Child activity centers — facilities clarification states that Sections 9.1.1.1.6, 9.1.1.1.7, and 9.1.1.1.8 also apply to this section, except that the sign advising users to wash hands (in section 9.1.1.1.6) is not required.

---

### Standards of care in diabetes – 2025 [^5c059b62]. Diabetes Care (2025). High credibility.

Regarding specific circumstances for hypertension, more specifically with respect to patients with diabetes mellitus, lifestyle modifications, ADA 2025 guidelines recommend to advise lifestyle interventions in patients with BP > 120/80 mmHg, consisting of weight loss when indicated, a DASH-style eating pattern (including reducing sodium and increasing potassium intake), moderation of alcohol intake, smoking cessation, and increased physical activity.

---

### Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5 [^6d2dfdda]. Obesity (2020). Medium credibility.

TABLE 2
Key eligibility criteria for STEP trials

Adults are excluded from the trials if there is a self‐reported change in body weight of > 5 kg within 90 days before screening. For trials that excluded patients with T2D (STEP trails 1, 3, 4, and 5), adults are excluded if they have a history of type 1 diabetes mellitus or T2D mellitus, HbA 1c ≥ 6.5% (48 mmol/mol), or previous treatment with glucose‐lowering agents or any AOM within the past 90 days before screening.

For all trials, treatment discontinuation can be decided by the investigator or participant. After discontinuation, participants are encouraged to continue to attend visits per the schedule and may be given the option to restart trial medication. Protocol‐specified discontinuation criteria include safety concerns from the investigator, calcitonin level ≥ 100 ng/L, suspicion of pancreatitis, pregnancy or intention to become pregnant, and participation in another clinical trial. Participants can withdraw consent at any point and are considered lost to follow‐up if they repeatedly fail to attend scheduled visits and cannot be contacted.

The protocols allow for dose reductions in case a participant does not tolerate the recommended target dose of 2.4 mg and may stay at the lower dose level of 1.7 mg once weekly, if needed. This is only allowed if the participant would otherwise discontinue trial treatment completely and if it is considered safe to continue trial treatment, per the investigator's discretion. It is recommended that the participant make at least one attempt to re‐escalate to the recommended target dose of 2.4 mg once weekly. Dose is recorded at selected visits throughout the trials.

Outcome measures

The primary and confirmatory secondary end points are described in Table 1. For all trials, the primary endpoints are percentage change from baseline at randomization (note that this was from week 20 in STEP 4) to end of treatment (EOT) in body weight and ≥ 5% WL from baseline after EOT (not applicable for the sustained WM trial [STEP 4]). Confirmatory secondary trial endpoints include the proportion of participants achieving a body weight reduction ≥ 10% or ≥ 15% from baseline to EOT (not applicable for the sustained WM trial [STEP 4]). Other confirmatory secondary endpoints for all the trials are change from baseline to EOT (or change from randomization [week 20] to EOT for the sustained WM trial [STEP 4]), in waist circumference (centimeters), systolic blood pressure (millimeters of mercury), and clinical outcome assessments.

---

### EAU guidelines on urethral strictures [^f61dda26]. EAU (2025). High credibility.

Regarding follow-up and surveillance for urethral stricture, more specifically with respect to follow-up, EAU 2025 guidelines recommend to obtain cystoscopy or retrograde urethrography to assess anatomic success after urethroplasty surgery.

---

### Polyneuropathy quality measurement set: quality improvement in neurology [^5da78b6e]. Neurology (2022). High credibility.

Figure 2 — Development steps for the polyneuropathy quality measures outline a process in which outcome measure concepts proposed (N = 24) undergo data review via concept ranking to an outcome concept drafted (n = 1) with draft guideline statements reviewed, while process concepts proposed (n = 3) lead to measures advanced (n = 3): Process (2) and Outcome (1), followed by public comment and refinement and culminating in measures approved (n = 3).

---

### Diagnosis, management and treatment of the Alport syndrome-2024 guideline on behalf of ERKNet, ERA and ESPN [^45eede36]. Nephrology, Dialysis, Transplantation (2025). High credibility.

Regarding diagnostic investigations for Alport syndrome, more specifically with respect to hearing assessment, ERA/ERN ERKNet/ESPN 2025 guidelines recommend to consider obtaining a hearing evaluation at diagnosis or upon reaching adulthood in female patients with X-linked alport syndrome, and then every 5 years in the absence of hearing loss symptoms.

---

### Evaluating the performance of large language&visual-language models in cervical cytology screening [^62d38023]. NPJ Precision Oncology (2025). Medium credibility.

Unformatted answers processing

We instructed the models to answer in a specific format for each task (Supplementary Note 2d) and subsequently performed a validity check on the format of answers (Supplementary Table 1). For close-ended and open-ended tasks in QA datasets, as well as close-ended tasks in the VQA dataset, we required the answers to be formatted in JSON, consisting of two key-value pairs: "answer" and "reason". Due to the context length limitation of ViLT and the capability constraint of Qwen-VL, we were unable to collect answers from them in JSON format and only requested unformatted answers. Subsequently, we converted these unformatted answers into the correct format using GPT-4. For open-ended tasks in the VQA dataset, imposing strict formatting requirements could negatively affect the quality of the answers due to the complexity of the task. Therefore, all models provide answers in an unformatted form. There were four types of unformatted answers: formatting issues, blank responses, unexpected returns, and refuse to answer (Supplementary Table 1), which corresponded to cases where the model did not adhere to the prescribed JSON format, produced blank responses for unknown reasons, exhibited incorrect answer format due to a misunderstanding of the question (e.g. answering open-ended questions in a close-ended format or generating irrelevant contents), and avoided directly answering the question, respectively. We only retested answers with formatting issues and blank responses. Since answers with formatting issues were automatically retested by an error correction program within the pipeline, we did not record their occurrence. The remaining two types of answers reflected the comprehension capability of the model, and thus, no additional processing was performed.

---

### Standards of care in diabetes – 2025 [^57391c23]. Diabetes Care (2025). High credibility.

Regarding specific circumstances for diabetes mellitus type 1, more specifically with respect to pediatric patients (physical activity), ADA 2025 guidelines recommend to advise frequent glucose monitoring before, during, and after exercise, via a blood glucose meter and/or continuous glucose monitoring, to prevent, detect, and treat hypoglycemia and hyperglycemia associated with exercise.

---

### Urethral stricture disease guideline amendment (2023) [^b0f1bd52]. The Journal of Urology (2023). High credibility.

Regarding follow-up and surveillance for urethral stricture, more specifically with respect to management of recurrent strictures, AUA 2023 guidelines recommend to perform urethroplasty rather than repeating endoscopic management in patients with recurrent anterior urethral strictures following failed dilation or direct visual internal urethrotomy.

---

### 2023 ACC / AHA / ACCP / HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology / American Heart Association joint committee on clinical practice guidelines [^18c6db10]. Circulation (2024). High credibility.

Regarding surgical interventions for atrial fibrillation, more specifically with respect to LAA closure, indications, ACC/ACCP/AHA/HRS 2024 guidelines recommend to consider performing percutaneous LAA occlusion in patients with AF, a moderate-to-high risk of stroke (CHA2DS2-VASc score ≥ 2), and contraindications to long-term oral anticoagulation due to a nonreversible cause.

---

### Standards of care in diabetes – 2025 [^2a4976a0]. Diabetes Care (2025). High credibility.

Regarding specific circumstances for chronic kidney disease, more specifically with respect to patients with diabetes mellitus, renin-angiotensin system inhibitors, ADA 2025 guidelines recommend to monitor for increased serum creatinine and for increased serum potassium levels when ACEis, ARBs, or mineralocorticoid receptor antagonists are used, or for hypokalemia when diuretics are used at routine visits and 7–14 days after initiation or after a dose change.

---

### Findings from a novel approach to publication guideline revision: user road testing of a draft version of SQUIRE 2.0 [^d291ed20]. BMJ Quality & Safety (2016). Medium credibility.

The last instance comes from the use of the two items 'the logic on which the improvement was based, including mechanism by which improvement expected to work' and 'process and outcome measures used for the improvement, including rationale for choice… '. The open-ended question about the logic on which the improvement was based elicited a range of answers; some were inconsistent with the developers' intent, while others were not complete. Neither the logic item nor the process and outcome measures items — which are somewhat interrelated — were generally used as intended. These findings are also consistent with the findings in the evaluation of SQUIRE 1.0; participants in that study identified these as difficult concepts. The above-noted items will need explicit explanation and instruction in SQUIRE 2.0

We hypothesise that issues with usage and interpretation of items were primarily a result of the ongoing evolution of the field, as it draws from and expands upon multiple areas of knowledge.SQUIRE 2.0 could help by explicitly pointing people to the developing resources. However, it is also true that the concepts associated with some of the SQUIRE items are difficult and necessitate wide-ranging knowledge that will be new for many who are joining the field from either clinical practice or health administration. Some require in-depth understanding of issues of establishing internal validity in research design (items 10a–10e in the SQUIRE 1.0 Guidelines; and the items under the section labelled 'improvement' in SQUIRE 1.6), which may not be familiar to people not well grounded in a clinical research background. Other concepts come from the social sciences (eg, the 'logic and mechanisms' item in SQUIRE 1.6) and would likely be unfamiliar to people without a firm background in implementation or public health intervention development.

---

### 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-thoracic Surgery (EACTS) [^edec6a8b]. European Heart Journal (2024). High credibility.

Regarding surgical interventions for atrial fibrillation, more specifically with respect to LAA closure, indications, EACTS/ESC 2024 guidelines recommend to consider performing percutaneous LAA occlusion in patients with AF and contraindications for long-term anticoagulant treatment to prevent ischemic stroke and thromboembolism.

---

### 2025 ESC guidelines for the management of myocarditis and pericarditis [^b050a21b]. European Heart Journal (2025). High credibility.

Regarding nonpharmacologic interventions for myocarditis, more specifically with respect to physical activity restrictions, ESC 2025 guidelines recommend to restrict physical exercise until remission for at least 1 month in athletes and non-athletes after inflammatory myopericardial syndrome, using an individualized approach to accelerate recovery.

---

### Standards of care in diabetes – 2025 [^14753c0e]. Diabetes Care (2025). High credibility.

Regarding specific circumstances for chronic kidney disease, more specifically with respect to patients with diabetes mellitus (monitoring of renal function), ADA 2025 guidelines recommend to monitor urinary albumin (such as spot urinary albumin-to-creatinine ratio) and eGFR 1–4 times per year, depending on the stage of the disease, in patients with established diabetic kidney disease.

---

### Defining the time-limited trial for patients with critical illness: an official American Thoracic Society workshop report [^cf1ee11e]. Annals of the American Thoracic Society (2024). High credibility.

Time-limited trial in critical care — essential elements and phased process were derived through a Delphi process: investigators "identified 18 potential steps" and found first-round consensus that "11 of these were essential elements"; during the second round, they "identified seven additional essential elements." The committee then "combined 4 related items into two steps (to reach 16 essential elements)" and "organized steps into four phases of care: consider, plan, support, and reassess." Additional steps "may be helpful in some cases, but not necessary for all trials," and involvement of other disciplines is "highly dependent on a patient's specific situation and on the available hospital resources."

---

### EAU guidelines on paediatric urology [^f7a3345e]. EAU (2025). High credibility.

Regarding follow-up and surveillance for hypospadias, more specifically with respect to postoperative follow-up, EAU/ESPU 2025 guidelines recommend to recognize that:

- low surgeon volume increases the risk of fistula, stricture and diverticulum

- up to half of complications requiring re-operation present after the first year postoperatively

- obstructive flow curve is common after hypospadias repair and most of which are not clinically significant

- urine flow is significantly lower after hypospadias surgery, especially in chordee correction, but without significant association with lower urinary symptoms.

---

### UK guidelines on oesophageal dilatation in clinical practice [^75e42ab6]. Gut (2018). Medium credibility.

Regarding therapeutic procedures for esophageal stricture, more specifically with respect to endoscopic dilation (postprocedural assessment), BSG 2018 guidelines recommend to perform endoscopic re-inspection in patients becoming symptomatic while in the procedure room to assess for the presence of perforation and to initiate treatment, including immediate endoscopic stent placement.

---

### Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials [^f36f294e]. Obesity (2025). Medium credibility.

FIGURE 1
Treatment intensity changes from randomization to end of treatment in the Semaglutide Treatment Effect in People with Obesity (STEP) 1, 3, 6, and 8 and STEP 2 and 6 pools in participants treated with (A, B) antihypertensives and (C, D) lipid‐lowering medications at randomization.

In both the STEP 1, 3, 6, and 8 and STEP 2 and 6 pools, treatment intensity was monitored from randomization to end of treatment in participants treated with lipid‐lowering medications at randomization (Figure 1C, D). A majority of participants in the semaglutide 2.4 mg and placebo groups continued lipid‐lowering treatment from randomization to week 68 (STEP 1, 3, 6, and 8: 89.9% and 95.5%, respectively; STEP 2 and 6: 89.5% and 94.6%, respectively). The semaglutide 2.4 mg group had a higher proportion of participants who discontinued all lipid‐lowering medications compared with the placebo groups (STEP 1, 3, 6, and 8: 10.1% and 4.5%, respectively; STEP 2 and 6: 10.1% and 5.4%, respectively). In the STEP 1, 3, 6, and 8 pool, a similar proportion of participants underwent a treatment intensity reduction (4.0% and 3.9% for semaglutide 2.4 mg and placebo, respectively), and a smaller proportion of participants in the semaglutide 2.4 mg group underwent a lipid‐lowering treatment intensification compared with the placebo groups (2.1% and 9.7%, respectively). In the STEP 2 and 6 pool, a larger proportion of participants continuing lipid‐lowering medications had a treatment intensity reduction in the semaglutide 2.4 mg group versus the placebo groups (4.6% and 0.9%, respectively); however, treatment intensification was similar between both the semaglutide 2.4 mg and placebo groups (2.9% and 4.5%, respectively) by week 68. Most participants continuing lipid‐lowering treatment at week 68 had no change in treatment intensity.

---

### Synopsis of the 2020 U.S. VA / DoD clinical practice guideline for the management of adult overweight and obesity [^48a03135]. Military Medicine (2021). High credibility.

Figure A-1 study flow diagram — the literature review inclusion/exclusion process is presented as a flow chart with nine labeled boxes, with arrows down indicating the next step and arrows right indicating excluded citations. Searches identified 7,027 citations (Box 1), 5,440 were excluded at the title level, and 1,587 abstracts were reviewed; at the abstract level, 932 citations were excluded, leaving 655 full-length articles reviewed. At first pass full article review, 349 citations were excluded, and 306 articles were reviewed. At second pass full article level, 199 citations were excluded for the following reasons: 36 wrong study design or doesn't address a KQ, 70 not an intervention or comparator of interest, 7 no outcome of interest, 3 not a study population of interest, 3 unclear or inadequate follow-up, 12 inadequate reporting of data/no data extract, and 11 other; down to 107 included studies.

---

### Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension [^cbf53ee8]. Diabetes, Obesity & Metabolism (2022). Medium credibility.

3.2 Change in body weight and

During the main treatment phase (from baseline [week 0] to week 68), semaglutide reduced body weight more than placebo (Figure 1A and Tables 2 and S1); observed mean weight loss was 17.3% (standard deviation [SD]: 9.3%) with semaglutide versus 2.0% (SD: 6.1%) with placebo (Table S1). After treatment withdrawal, body weight regain was observed in both the semaglutide and placebo arms (Figure 1A and Tables 2 and S1). Participants regained a mean of 11.6 percentage points (SD: 7.7) of body weight in the semaglutide arm versus 1.9 percentage points (SD: 4.8) in the placebo arm (Table S1). The net mean body weight loss over the full duration of the main treatment phase and off‐treatment extension phase (from week 0 to week 120) was 5.6% (SD: 8.9%) in the semaglutide arm versus 0.1% (SD: 5.8%) in the placebo arm (Figure 1A). At week 120, 5% or higher weight loss from baseline was observed in 48.2% of participants (95 of 197) in the semaglutide arm and in 22.6% (21 of 93) in the placebo arm.

---

### Canadian Urological Association guideline on male urethral stricture [^1db9f6bb]. Canadian Urological Association Journal = Journal de L'Association des Urologues du Canada (2020). High credibility.

Regarding follow-up and surveillance for urethral stricture, more specifically with respect to management of recurrent strictures, CUA 2020 guidelines recommend to consider performing urethroplasty rather than repeating endoscopic management (direct visual internal urethrotomy or dilation) in patients with a recurrent urethral stricture failing prior endoscopic treatment.

---

### Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses [^8785ac70]. Diabetes, Obesity & Metabolism (2023). Medium credibility.

2 MATERIALS AND METHODS

The methodology of STEP 1 and 4 has been described previously.

2.1 Study designs

STEP 1 (NCT03548935) was a double‐blind, placebo‐controlled trial (Figure S1). Participants were randomized 2:1 to once‐weekly s.c. semaglutide 2.4 mg or placebo, with lifestyle intervention for 68 weeks. STEP 4 (NCT03548987) was a randomized withdrawal trial in which all participants received semaglutide during a 20‐week run‐in period (Figure S2). Participants reaching the once‐weekly s.c. semaglutide 2.4 mg target maintenance dose at week 20 were randomized 2:1 to continue semaglutide or switch to placebo for 48 weeks. All participants received lifestyle intervention throughout the 68 weeks.

Both trials were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Protocols were approved by independent ethics committees or institutional review boards at each study site. All participants provided written informed consent.

2.2 Study population

Participants in both trials were aged ≥ 18 years with one or more self‐reported unsuccessful dietary effort to lose weight and body mass index ≥ 30 kg/m 2 or ≥ 27 kg/m 2 with one or more weight‐related comorbidity without diabetes.

2.3 Outcomes and assessments

The endpoints assessed are detailed below, with information on how they were measured in the Supporting Information.

---

### Diagnosis and classification of diabetes: standards of care in diabetes – 2025 [^568cafd9]. Diabetes Care (2025). High credibility.

Type 1 diabetes natural history and progression risk indicate that stage 1, defined by the presence of two or more autoantibodies and normoglycemia, carries a 5-year risk of developing symptomatic type 1 diabetes of ~44%. In stage 2, risk is ~60% by 2 years and ~75% within 5 years of developing a clinical diagnosis of type 1 diabetes. A consensus group provides expert recommendations on what should be monitored and how often these factors should be monitored in individuals with presymptomatic type 1 diabetes.

---

### An introduction to systematic reviews in respiratory medicine [^65dcf71e]. Respiratory Medicine (2003). Low credibility.

Reviews are an essential component of modern medicine. The volume of literature is large, even about a single treatment for pulmonary disease. The task of retrieving all the relevant papers, then assessing the evidence to reach a valid conclusion is very time consuming. At every stage there is the risk of sampling error (failure to get all the evidence) and bias (a systematic distortion of the results due to a weakness in the methodology). There are essentially two types of review: narrative reviews that follow no rules, exposing them to sampling error and bias; and systematic reviews that attempt to minimise these effects by following an explicit structure for retrieving all of the evidence and attempting an objective synthesis of the results from the different trials. A good review can serve a number of purposes including: assembling all the relevant evidence in one place, providing a valid estimate of the overall effect of treatment, producing guidance for clinical practice and generating hypotheses for further trials about patients or settings in which the treatment effect may be less or more effective.

---

### Standards of care in diabetes – 2025 [^9fec4de9]. Diabetes Care (2025). High credibility.

Regarding follow-up and surveillance for diabetes mellitus type 1, more specifically with respect to continuous glucose monitoring, ADA 2025 guidelines recommend to assess skin reactions, either due to irritation or allergy, and address to aid in successful use of devices.

---

### Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2025 report) [^bb2b1d80]. GOLD (2025). High credibility.

Remote COPD follow-up visit — procedural steps are outlined to structure the encounter. Instructions include to describe what to do if the connection fails, explain that this is a remote visit and give the reason why, check if there are others listening and whether the patient consents to all those present, set the agenda, and conduct the follow-up using the COPD Follow-up Checklist while focusing on the patient's main issues; then end and summarize the visit by asking the patient to summarize, setting a date for follow-up, and agreeing upon ending the meeting.

---

### Global strategy for asthma management and prevention [^da0a3408]. GINA (2024). High credibility.

Asthma exacerbation follow-up and referral — after an exacerbation, the written asthma action plan should be reviewed, and maintenance asthma treatment can generally be reduced to previous levels 2–4 weeks after the exacerbation unless the history suggests long-term poorly controlled asthma, in which case a step up in treatment may be indicated. Patients with more than 1–2 exacerbations per year despite Step 4–5 therapy (or Step 4 therapy in children 6–11 years), or with several emergency department visits, should be referred to a specialist center, if available, for assessment and strategies to reduce their risk of future exacerbations and their risk of exposure to OCS.

---

### Colorectal cancer screening and prevention [^c270f773]. American Family Physician (2025). High credibility.

Regarding screening and diagnosis for colon cancer, more specifically with respect to indications for screening, general population, aged 76–85 years, AAFP 2025 guidelines recommend to consider obtaining screening for CRC in adults aged 76–85 years at average risk based on overall health status, prior screening history, and patient preferences.

---

### Standards of care in diabetes – 2025 [^39f7c162]. Diabetes Care (2025). High credibility.

Regarding diagnostic investigations for diabetes mellitus type 1, more specifically with respect to screening for diabetic foot, ADA 2025 guidelines recommend to elicit a history of ulceration, amputation, Charcot foot, angioplasty or vascular surgery, cigarette smoking, retinopathy, and renal disease and assess current symptoms of neuropathy (pain, burning, numbness) and vascular disease (leg fatigue, claudication).

---

### Roflumilast (Zoryve) [^e2de6cd7]. FDA (2024). Medium credibility.

The dosage of roflumilast TOP for treatment of plaque psoriasis in adults is 1 application(s) TOP daily (0.3% cream or foam)

---

### Evidence-based guidelines for fatigue risk management in emergency medical services [^60fd1b73]. Prehospital Emergency Care (2018). Medium credibility.

Evidence Based Guidelines (EBGs) development methods — Model Process steps, public input, panel formation, and research questions — are specified. The development of these guidelines followed recommendations of the 8-step Model Process for the creation of prehospital EBGs, with the primary aim to create EBGs for fatigue risk management that are tailored to the EMS workplace. External Input (Step 1) was solicited through public comment periods during project-related meetings in April 2016 and via an online solicitation on a designated project website. Guideline Initiation and Evidence Review (Step 2) was accomplished by forming a panel of experts with knowledge of and experience in sleep medicine, fatigue science, emergency medicine, EMS, risk management, administration, and consumers; the panel's configuration satisfied the Institute of Medicine's recommendation of diversity in expertise, experience, and content knowledge. Table 1 lists members of the expert panel and notes that Mr. Eisnach discontinued participation on the panel before February 2017 due to illness. The panel produced seven research questions framed in the Population, Intervention, Comparison, and Outcomes (PICO) format.

---

### 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death [^16d4bad7]. European Heart Journal (2022). High credibility.

Regarding medical management for syncope, more specifically with respect to management of cardiac arrhythmia-induced syncope, long QT syndrome, ESC 2022 guidelines recommend to consider placing an ICD in patients with Andersen-Tawil syndrome with a history of unexplained syncope.

---

### False positives in breast cancer screening with one-view breast tomosynthesis: an analysis of findings leading to recall, work-up and biopsy rates in the malmöbreast tomosynthesis screening trial [^6e9cfa34]. European Radiology (2016). Low credibility.

Results

FP recall rate after arbitration

Out of 7,500 screened women a total of 352 were recalled for work-up. Three women were excluded from the analysis, including one woman diagnosed with lymphoma and two women declining the work-up. Sixty-eight women were shown to have breast cancer and 281 were FPs. FP recall rate after arbitration for BT alone was 1.7% (n = 131), for DM alone 0.9% (n = 69) and for women recalled on both BT+DM 1.1% (n = 81) (Fig. 1). The majority of the cases were selected at reading step 1 (Table 1). The contribution of FP cases with the addition of prior DM was minor in the BT-alone and DM-alone recall groups (two cases per group). As expected, symptomatic women were mainly found in the BT+DM recall group.

Fig. 1
False-positive recall rate over time. False-positive recall rate for breast tomosynthesis (BT) alone, digital mammography (DM) alone and for cases recalled on both BT+DM during the first half of the Malmö Breast Tomosynthesis Screening Trial

Table 1
Reading steps. Number of positive scores (rated 3 or higher) in the recall groups that resulted in a false-positive case in the two independent reading arms: Reading arm BT: one-view breast tomosynthesis (BT) alone (step 1); the addition of one-view digital mammography (DM) craniocaudal view (step 2); comparison with prior two-view DM, if available (step 3). Reading arm DM: two-view DM (step 1); and comparison with prior DM (step 2)

The mean FP recall rate over time (1.5 years) for BT alone was 1.9% (range 1.5–3.3), for DM alone 0.9% (range 0.4–1.2) and for BT+DM 1.0% (range 0.6–1.5). The FP recall rate for BT alone was halved during the first 1.5 yeary of the MBTST, stabilising on an FP recall rate of about 1.5% (Fig. 1).

---

### Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update [^4c5db8f6]. The Journal of Clinical Endocrinology and Metabolism (2020). High credibility.

Regarding medical management for postmenopausal osteoporosis, more specifically with respect to antiresorptive and anabolic therapy, romosozumab, ES 2020 guidelines recommend to initiate romosozumab for up to 1 year to reduce the risk of vertebral, hip, and non-vertebral fractures in postmenopausal patients with osteoporosis at very high risk of fractures, such as with severe osteoporosis (low T-score < -2.5 and fractures) or multiple vertebral fractures. Switch to an antiresorptive therapy to maintain bone density gains and reduce fracture risk in postmenopausal patients with osteoporosis completing a course of romosozumab. (1, Moderate).

---

### Standards of care in diabetes – 2025 [^d89192ca]. Diabetes Care (2025). High credibility.

Regarding nonpharmacologic interventions for diabetes mellitus type 1, more specifically with respect to physical activity, ADA 2025 guidelines recommend to assess baseline physical activity and time spent in sedentary behavior (quiet sitting, lying, and leaning) in all patients with diabetes. Encourage increasing physical activities (such as walking, yoga, housework, gardening, swimming, and dancing) above baseline in patients not meeting activity guidelines.

---

### Roflumilast (Zoryve) [^11a5acd0]. FDA (2024). Medium credibility.

The dosage of roflumilast TOP for treatment of plaque psoriasis in both children (in patients 6–12 years) is 1 application(s) TOP daily (0.3% cream)

---

### Investigating suspected cancer clusters and responding to community concerns: guidelines from CDC and the council of state and territorial epidemiologists [^945666c0]. MMWR: Recommendations and Reports (2013). Medium credibility.

Cancer cluster investigation — Step 2 decision to close or proceed to Step 3 is based on multiple factors, and to interpret the standardized incidence ratio (SIR) the health agency must assess whether there are enough cases and population for statistical stability and, in general, that the population size of a typical census tract is the smallest denominator that will allow reliable results; if the numerator allows stability, agencies should consider whether the 95% CI exclude 1.0, along with environmental contaminants, population changes, and other information beyond the SIR to estimate whether cancers represent an excess and share a common etiology. A SIR of limited magnitude that is not statistically significant with lack of known contaminant association and no increasing trend justifies closing at Step 2, whereas a statistically significant SIR of great magnitude with an increasing trend and a known contaminant argues for continuing to Step 3; example thresholds indicate that an SIR of < 2.0 with CIs surrounding or overlapping 1.0 and < 10 cases might justify closing, while an SIR of > 4 with CIs not overlapping 1.0 and ≥ 10 etiologically linked cases should encourage advancing to Step 3.

---

### Stepwise evaluation for the risk of metabolic unhealthiness and significant non-alcoholic fatty liver disease in India [^f3b1caf1]. The Lancet Regional Health: Southeast Asia (2023). High credibility.

Performance of stepwise evaluation for detecting subjects at risk of metabolic disorder

As the study was designed to screen the subjects at metabolic risk at every step of evaluation, proportion of these subjects showed an increasing trend across the steps, though, test of significance for these differences are not logically acceptable and thus avoided. Proportion of Subjects with BMI < 23 kg/m 2 decreased from 83.2% (n = 66,525) in the first-step to 74.8% (n = 7342) in second-step and 65.6% (n = 920) in the third-step (Table 1). Subjects with abdominal obesity increased from 14.1% (n = 11,279) in the first-step to 23.8% (n = 2336) and 28.1% (n = 394) in second and third steps, respectively (Table 1). Similarly, frequencies of hypertensive subjects increased from first to third step. Subjects with IFG (Prediabetes)/Diabetes were more prevalent in third-step than second-step evaluation [n (%); 939 (66.9) and 2431 (24.8) in third and second step, respectively] (Table 1). Frequency of elevated ALT, also, increased in third-step [n (%); 958 (68.3) and 3881 (39.5) in third and second step, respectively] (Table 1).

---

### 2019 ACC / AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology / American Heart Association task Force on Clinical practice guidelines [^dec2883c]. Journal of the American College of Cardiology (2019). High credibility.

ACC/AHA 2019 primary prevention — blood pressure thresholds and treatment algorithm specifies: Normal BP (BP < 120/80 mm Hg) prompts "Promote optimal lifestyle habits"; Elevated BP (BP 120–129/ < 80 mm Hg) leads to "Nonpharmacological therapy (Class I)." For Stage 1 hypertension (BP 130–139/80–89 mm Hg), the pathway assesses "Estimated 10-y CVD risk ≥ 10%"; at this threshold the action is "Nonpharmacological therapy and BP-lowering medication (Class I)" and when not at this threshold the action is "Nonpharmacological therapy (Class I)." Stage 2 hypertension (BP ≥ 140/90 mm Hg) is treated with "Nonpharmacological therapy and BP-lowering medication (Class I)."

---

### Sodium chloride (Alfa 0.9% sodium chloride) [^fa103789]. FDA (2025). Medium credibility.

STORAGE

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing.

---

### Towards generalist foundation model for radiology by leveraging web-scale 2D&3D medical data [^44c91c24]. Nature Communications (2025). High credibility.

Visual instruction datasets. For samples from visual instruction datasets like PMC-VQAor PMC-CaseReport, they are often in the format of dialogue, for example, "What can you see from the image? 〈image-1〉 I can see lesions." or "Please describe the scans 〈image-1〉. The scan is… ", we further separate the language partinto instruction and response, denoted asandrespectively. For example, as in the former two cases, refers to "What can you see from the image? 〈image-1〉 " and "Please describe the scans 〈image-1〉 ". In a practical scenario, is expected to be given by users, and the model is only required to output correct responses. Overall, w l can be formulated as, Most samples from MedMD fit the weighting formulation. All prompts used for instruction tuning are listed in the Supplementary Tables 8–11. We describe the detailed prompting for different problem settings:
Modality recognition. Here, we adopt two types of prompts, (i) we use inductive prompts, and the 2D or 3D medical scan as input, for example, "〈image-1〉 Is this image captured by {modality}?", and the modality category is randomly sampled from the modality set, forming the text inputand if the modality matches the ground truth labels we set theas "yes" otherwise "no". (ii) we use open prompts, like "What's the modality of the input scan 〈image-1〉 ?" to form the, and translate the corresponding modality label into. Samples for training such functionality are from RP3D-Modality and MPx-Single, with modality annotations available.
Disease diagnosis. All the datasets listed as "image data" in Supplementary Table 3 are built for diagnosis, they only have binary labels for diseases. Similarly to modality recognition, we use two prompts to transform them into our desired format, (i) we use inductive prompts, like "〈image-1〉 Does the patient have {disease}?" and the disease category is randomly sampled from a disease set, forming the text inputand if the disease matches the ground truth labels we set theas "yes" otherwise "no", note that, during sampling, we balance the positive and negative ratio, (ii) we use open diagnosis prompts, like "Please make diagnosis based on the images 〈image-1〉 〈image-2〉." to construct the instruction, and translate the positive disease labels into response, by simply using their category names. A simple example is, = "Please make diagnosis based on the image 〈image-1〉." with = "Edema, pneumothorax.". With such instruction, the model is thus required to complete a difficult task, i.e. directly outputting the disease name.
Visual question answering. Beyond the abovementioned task formulation, there are more complex questions that can be asked, such as those about the spatial relationships among objects ("What is the location of the lesion?") and common sense reasoning questions ("Given the image context and patient history, what is likely to be the cause of the observed symptoms?"). A robust medical VQA system must be capable of solving a wide range of classic medical diagnosis tasks, as well as the ability to reason about images. Existing medical VQA datasets like VQA-RAD, SLAKE, PMC-VQAand RP3D-VQA naturally fit into this paradigm. They contain a mixture of question types, thus the language questions can naturally be treated as text instruction and the corresponding answer as response. It is worth noting that, our constructed PMC-CaseReport dataset also falls into this category, with more contextual information available for instruction, for example, history diagnosis, is also available, thus providing critical information for answering the question.
Report generation. MIMIC-CXR, RP3D-Caption, PMC-OA, MPx-Multi, and MPx-Single are all captioning datasets, the task is to write a long caption or report given one or a set of images. The language instruction for this task are like "What can you find from the scans 〈image-1〉 〈image-2〉?".
Rationale diagnosis. We construct RP3D-Rationale based on the RP3D dataset. This task encompasses disease prediction and the generation of typical radiological features associated with the diagnosed disease. Specifically, we design some prompts like "What disease can be diagnosed from these radiological images and what specific features are typically observed on the images? 〈image-1〉 〈image-2〉 " as instruction, and response refers to the disease label along with radiological features collected from the Radiopaedia website.

---

### Standards of care in diabetes – 2025 [^634f3c56]. Diabetes Care (2025). High credibility.

Regarding diagnostic investigations for diabetes mellitus type 1, more specifically with respect to screening for diabetic neuropathy, ADA 2025 guidelines recommend to elicit a careful history and assess either temperature or pinprick sensation (small-fiber function) and vibration sensation using a 128-Hz tuning fork (for large-fiber function) for the assessment of distal symmetric polyneuropathy. Obtain annual 10-g monofilament testing in all patients with diabetes to identify feet at risk for ulceration and amputation.

---